Uric acid and fructose: an overlooked metabolic driver, beyond gout

Uric acid is the waste product your body makes when it breaks down purines, the building blocks of DNA and of certain foods. For two thousand years it has been known mainly as the cause of gout. The newer and more contested idea, championed by the American physician Richard Johnson and colleagues, is that uric acid is not just a marker of metabolic trouble but an active driver of it, raised in a peculiar way by fructose, and feeding into insulin resistance, fatty liver, high blood pressure and weight gain. The honest position in 2026 is in between: the laboratory mechanism is real and elegant, the human associations are strong, but the genetic evidence that uric acid actually causes metabolic disease is weak and inconsistent. This article separates the two carefully.

What uric acid actually is

Purines are nitrogen-rich molecules found in every cell, both in your own tissue and in the food you eat. When cells turn over, or when you digest purine-rich foods, those purines are broken down in a chain of steps to a final product called uric acid. In most mammals an enzyme called uricase then degrades uric acid further into a soluble, harmless compound. Humans and the other great apes lost a working uricase gene millions of years ago through mutation, so our breakdown chain stops one step early, leaving uric acid as the end product.¹ That is why our blood urate levels sit far higher than those of almost every other animal, and it is the evolutionary quirk that makes the whole story possible.

The body holds urate in a narrow range, balancing what it makes against what the kidneys and gut excrete. When production outpaces excretion, blood levels rise: this is hyperuricaemia. Above a solubility threshold, urate can crystallise out of solution, which is the proximate cause of gout.²

The classic role: gout and kidney stones

Gout is what happens when urate crystallises. When blood urate stays above its solubility limit, needle-shaped monosodium urate crystals form in and around joints, most famously the base of the big toe. The immune system attacks these crystals, producing the sudden, excruciating, red-hot flare that defines acute gout.² Persistently high urate can also crystallise in the urinary tract as uric acid kidney stones, and over years can deposit as lumps called tophi.

This part of the story is not controversial. The link between high urate and gout is causal, dose-dependent and reversible: lower the urate enough and crystals dissolve, flares stop and tophi shrink. Everything in this article that is solid sits here. The debate is entirely about whether urate does anything beyond crystals.

Why fructose is metabolically different

Glucose and fructose are often lumped together as sugar, but the liver handles them very differently, and that difference is the engine of the whole hypothesis. Glucose is phosphorylated by enzymes (hexokinases) that have a built-in brake: as the cell fills up, they slow down. Fructose is handled by a different enzyme, fructokinase, also called ketohexokinase or KHK, which has no such brake. It phosphorylates fructose as fast as it arrives.³

That unrestrained first step burns through the cell's energy currency, ATP, faster than it can be regenerated, causing a transient drop in cellular phosphate. The fall in phosphate switches on an enzyme (AMP deaminase) that pushes spare adenine nucleotides down a pathway ending in uric acid. So every pulse of fructose produces, as a near-inevitable by-product, a pulse of uric acid inside the cell and a measurable rise in the blood.³ No other common dietary sugar does this to anything like the same degree.

Laboratory work from Miguel Lanaspa, Johnson and colleagues then added a twist that makes the system self-amplifying. In cell and animal studies they found that uric acid itself ramps up fructokinase activity, partly by activating a master fat-making transcription factor (ChREBP). The result is a feed-forward loop: fructose makes uric acid, and uric acid makes the cell better at metabolising fructose into fat. Blocking uric acid production in those models markedly reduced fructose-driven fat accumulation in the liver.⁷

The Johnson hypothesis: uric acid as a driver

In a much-cited 2006 paper in Endocrinology and Metabolism, and a 2009 review in Endocrine Reviews, Johnson and colleagues proposed that the modern rise in fructose intake, mainly from sugar-sweetened drinks and processed food, raises uric acid, and that this uric acid is a causal mediator of the metabolic syndrome.⁸ The proposed chain runs roughly like this: fructose raises intracellular and serum uric acid; uric acid reduces the availability of nitric oxide in blood vessel walls; lower nitric oxide impairs insulin's ability to drive blood flow and glucose into muscle, producing insulin resistance; and uric acid simultaneously promotes oxidative stress in mitochondria and fat synthesis in the liver. Johnson later popularised this as a "survival switch" once useful for storing fat before winter or famine, now switched on permanently by year-round sugar.⁸

The supporting evidence is genuinely interesting. In animals, feeding fructose reliably reproduces features of the metabolic syndrome, and lowering uric acid (with drugs such as allopurinol) often prevents the high blood pressure, fatty liver and insulin resistance that fructose otherwise causes.⁷ In humans, observational studies consistently link higher urate with obesity, fatty liver, hypertension and diabetes. And some short randomised trials of urate-lowering drugs have shown modest improvements in insulin sensitivity and blood pressure.⁹ Our deeper dive into how insulin resistance develops sits alongside this as the metabolic backdrop.

The honest controversy: association versus causation

Here is where a calm reading diverges from the headlines. The associations are real, but association is not causation, and uric acid is a textbook case of the difference. High urate travels with obesity, alcohol, kidney impairment, insulin resistance and a Western diet, all of which independently cause metabolic disease. Untangling whether urate is a cause or merely a passenger is hard with observational data alone.

The most powerful tool we have for this is Mendelian randomisation, which uses genetic variants that raise lifelong urate as a kind of natural experiment, free of the usual confounding. If urate truly caused metabolic disease, people born with urate-raising genes should have more of it. Repeatedly, they largely do not. A large analysis by Tin, Pfister and colleagues and subsequent studies found that genetically higher urate is not convincingly associated with type 2 diabetes, fasting insulin or the metabolic syndrome, and a dedicated study found no causal effect of urate on triglycerides.⁵ A 2020 analysis of metabolic syndrome components reached the same conclusion: no causal evidence that urate drives the cluster.¹⁰

Blood pressure is the most interesting partial exception. A 2021 Mendelian randomisation and trial meta-analysis by Gill and colleagues found that genetically higher urate was associated with higher blood pressure and cardiovascular disease, with raised blood pressure appearing to mediate about a third of that effect.¹¹ Even here, results across studies are inconsistent, so the signal for blood pressure is suggestive rather than settled.

How can short trials of urate-lowering drugs show benefit if the genetics say urate is not causal? Several explanations coexist. The trials are small and often in selected groups; allopurinol does more than lower urate, including reducing oxidative stress directly via xanthine oxidase, so any benefit may not be from the urate drop itself; and a meta-analysis found urate-lowering improved some insulin-resistance markers and blood pressure but did not change fasting glucose, beta-cell function or lipids, which is not what you would expect if urate were a primary driver of diabetes.⁹ The pragmatic conclusion many researchers now hold: fructose clearly raises urate, and reducing free sugars is sound advice, but the urate rise is probably more of a fingerprint of harmful fructose handling than the weapon itself.

Where uric acid clearly matters

Stripped of the overreach, urate earns its place in a few clear situations. It is the proven cause of gout and of uric acid kidney stones, and lowering it treats both. It is worth checking if you have recurrent stones, unexplained joint flares, or are starting certain chemotherapy (where rapid cell breakdown can flood the system with purines).

Blood pressure in the young is the one metabolic area with real, if limited, human trial support. In a small but careful randomised crossover trial, Daniel Feig, Johnson and colleagues gave allopurinol to 30 adolescents with newly diagnosed, untreated hypertension and high urate. Allopurinol lowered systolic blood pressure by about 6.9 mmHg versus 2.0 mmHg on placebo.¹² That is a genuine effect, but it involved 30 teenagers, and the authors were explicit that allopurinol is not indicated for treating blood pressure. It is a clue, not a prescription.

UK context: NICE, allopurinol and the sugar levy

UK guidance is clean on this. The 2022 NICE gout guideline (NG219) recommends offering urate-lowering therapy, allopurinol or febuxostat, to people with gout using a treat-to-target approach, aiming for a serum urate below 360 micromol/litre, or below 300 micromol/litre for those with ongoing flares or tophi.⁶ Allopurinol is preferred first line for people with significant cardiovascular disease, partly reflecting the cardiovascular safety signals seen with febuxostat in the CARES trial, although the later FAST trial found febuxostat non-inferior and did not replicate the excess mortality.¹³ Crucially, none of this guidance positions urate-lowering drugs as a metabolic or cardiovascular prevention strategy for people without gout.

On the population side, the UK has acted on fructose at its most concentrated source. The Soft Drinks Industry Levy, in force since April 2018, taxes manufacturers by sugar content and prompted widespread reformulation: the share of drinks above the higher sugar threshold fell sharply, and tens of thousands of tonnes of sugar were removed from soft drinks annually.¹⁴ Sugar-sweetened drinks are the single largest avoidable source of fructose and the most consistently gout-associated, which is why they are the rational first target whatever you conclude about the deeper metabolic debate. If you are mapping your own diet and labs, our stack builder and evidence library can help you prioritise.

What to ask your GP

What to do next

This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.